Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, +17

The Lancet Oncology

Lymphoid NeoplasiaBispecific AntibodyMedicineImmunologyImmune Checkpoint Inhibitor +5

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J. Schuster, Nancy L. Bartlett, Sarit Assouline, +15

Blood

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S. Abramson, Matthew Ku, Mark P. Hertzberg, +23

The Lancet

Hematological MalignancyOpen-label TrialLymphoid NeoplasiaMedicineImmunology +6

The BTK Inhibitor, Bgb-3111, Is Safe, Tolerable, and Highly Active in Patients with Relapsed/ Refractory B-Cell Malignancies: Initial Report of a Phase 1 First-in-Human Trial

Constantine S. Tam, Andrew Grigg, Stephen Opat, +13

Blood

Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients

Nicole Wong Doo, Carole Soussain, Sylvain Choquet, +42

UCL Discovery (University College London)

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, +18

Blood

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the <scp>COVID</scp>‐19 pandemic

Pietro R Di Ciaccio, Georgia McCaughan, Judith Trotman, +30

Internal Medicine Journal

Twice Daily Dosing with the Highly Specific BTK Inhibitor, Bgb-3111, Achieves Complete and Continuous BTK Occupancy in Lymph Nodes, and Is Associated with Durable Responses in Patients (pts) with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Constantine S. Tam, Stephen Opat, Gavin Cull, +16

Blood

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance

Joel Wight, Mimi Yue, Colm Keane, +14

British Journal of Haematology

Subcutaneous Mosunetuzumab in Relapsed or Refractory B-Cell Lymphoma: Promising Safety and Encouraging Efficacy in Dose Escalation Cohorts

Matthew J. Matasar, Chan Y. Cheah, Dok Hyun Yoon, +17

Blood